Averin Capital
Venture capitalActively deployingNew York · Seed–Growth · 9 people tracked
Also known as AVERIN CAPITAL LLC
Investment thesis
Averin Capital invests where technology and health converge, supporting visionary teams driving significant shifts in human health—from early disease detection and improved treatment delivery to personalized care and major medical breakthroughs. Positioned as an operator-led firm, its team includes MDs, PhDs, experienced company founders, healthcare executives, and professionals from finance and consulting, having founded or launched over 30 companies. The firm combines scientific rigor, operational expertise, and strategic insight to help entrepreneurs scale. It emphasizes being a respectful partner of choice that knows when to engage and when to step back, aiming to empower exceptional teams to reach their fullest potential.
Source: firm website, verified Aug 3, 2026.
Team · 9 people
from the firm's website
What they invest in
from 3 of 12 portfolio companiesDigital Health ×3Healthtech ×3Medical Devices ×2AI & Machine Learning ×1Biotech ×1Consumer ×1
HQs:United States×3
Investments · 12 tracked
founders shown can be your intro path
Freenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesLondon
Riley Ennis(Co-Founder and Chief Product Officer)Stuart Lawson(Director)Charles Roberts(Director)Gabriel Otte(Director)
Austin, US
Prithviraj Singha Roy(Director)Nicholas Scott Aubin(Executive Officer, Director)Paulo Marques Da Costa(Executive Officer, Director)Brad Hively(Director)
BoardJohn Loser(Director)David Berry(Director)
Board seatTristan Hunt· per SEC Form D · $10.1M raise · filed Jul 2026
A product designed to be better for patients, easier and more cost-effective for practitioners while addressing market needs.
New York, US
Nicholas Greenfield(Executive Officer, Director)John Elton(Director)Jacob Goldfield(Director)Don Kingsborough(Director)Zachary Frankel(Executive Officer, Director)
Combines biosensors and GLP-1 receptor agonists to revolutionize diabetes care through real-time monitoring, personalized insights, and better blood sugar control with weight management.
A clinical-stage artificial intelligence company using Large Medicine Models to optimize drug development, especially in late-stage clinical trials.
A pioneering liquid biopsy company pursuing FDA approvals for cancer diagnostics with leading sensitivity and specificity.
Pine Park Health operates a team-based primary care model that provides medical care, preventive screening, and health coordination services for patients.
Digital HealthHealthtechSan Francisco, US
Payam Parvinchiha(Chief Medical Officer)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Frequently asked questions
- What stage does Averin Capital invest at?
- Averin Capital invests at the Seed, Series A, Series B, Series C, Growth stages.
- What sectors does Averin Capital focus on?
- Averin Capital focuses on AI & Machine Learning, Biotech, Digital Health, Healthtech, Longevity, Medical Devices, Robotics.
- Where is Averin Capital located?
- Averin Capital is headquartered in New York, US.
From the blog
visit blog ↗Averin Capital has written on structural barriers to AI adoption in biotech: talent loss driven by job design rather than compensation, liability gaps blocking clinical AI deployment, and state-level regulatory changes creating alternative pathways for experimental medicine commercialization." AI summary
Images
Similar investors
GV (formerly Google Ventures) is a venture investment firm that backs founders across many industries, aiming to build long-term relationships and support companies across multiple stages and milestones.
A globally recognized venture capital firm designed to provide access to highly competitive venture deals to individual investors, consistently recognized for top-decile DPI performance and as one of the most active US venture firms.
NJF Capital is the venture investment arm of NJF Holdings, the private investment group founded by Nicole Junkermann. It invests internationally in transformative technology companies.
JAZZ Venture Partners is a venture capital firm investing in companies at the intersection of technology, neuroscience, and human performance, spanning digital health, biosciences, and AI.
Brookstreet Equity Partners LLP is a family-office-originated GP established by shipping and principal-capital families, operating as an institutional investment manager focused on AI-driven investments across digital transformation, energy transition, longevity, and defence technology.